Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 871-874

  Thiele, Maja ^a   Wiest, Reiner ^b   Gluud, Lise Lotte ^c   Albillos, Agustín ^d   Krag, Aleksander ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BERN   (Switzerland)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

AR; BT; HCC; HCV; HVPG; LPS; NSBB; PAMP; TIPS; TLR4; VEGF

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; SORAFENIB; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; BACTERIAL VIRULENCE; BETA ADRENERGIC RECEPTOR BLOCKING; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; DRUG EFFECT; DRUG SELECTIVITY; ESOPHAGUS VARICES BLEEDING; FOLLOW UP; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HYPOTHESIS; IMMUNOLOGICAL TOLERANCE; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; RADIOFREQUENCY ABLATION; SAMPLE SIZE;

BACTERIA (MICROORGANISMS); HEPATITIS C VIRUS; RODENTIA;

BACTERIAL TRANSLOCATION; BETA-ADRENOCEPTORS; BT; HCC; HCV; HEPATIC VENOUS PRESSURE GRADIENT; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; HVPG; LIPOPOLYSACCHARIDE; LPS; NON-SELECTIVE BETA-BLOCKERS; NSBB; PAMP; PATHOGEN-ASSOCIATED MOLECULAR PATTERN; TIPS; TLR4; TOLL LIKE RECEPTOR 4; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; Β-AR;

ADRENERGIC BETA-ANTAGONISTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84886790527     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.026     Document Type: Article

References (58)

1. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. 2010, International Agency for Research on Cancer, Lyon, France.
3. Krag A., Wiest R., Albillos A., Gluud L.L. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012, 61:967-969.
4. Krag A., Wiest R., Gluud L.L. Reduced mortality with non-selective betablockers compared to banding is not related to prevention of bleeding or bleeding related mortality: systematic review of randomized trials. J Hepatol 2011, 54:S72.
5. Senzolo M., Cholongitas E., Burra P., et al. Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009, 29:1189-1193.
6. Pérez-Paramo M., Muñoz J., Albillos A., et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000, 31:43-48.
7. Wiest R., Krag A., Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012, 61:297-310.
8. Chim H., Armijo B.S., Miller E., Gliniak C., Serret M.A., Gosain A.K. Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Ann Surg 2012, 256:146-156.
9. Phillips C.B., Pacha O., Biliciler-Denkta G., Hebert A.A. A review of beta antagonist treatment for infantile hemangioma. J Drugs Dermatol 2012, 11:826-829.
10. Bangalore S., Kumar S., Kjeldsen S.E., et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324168 participants from randomised trials. Lancet Oncol 2011, 12:65-82.
11. Diaz E.S., Karlan B.Y., Li A.J. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012, 127:375-378.
12. Powe D.G., Voss M.J., Zanker K.S., et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010, 1:628-638.
13. Shah S.M., Carey I.M., Owen C.G., Harris T., DeWilde S., Cook D.G. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011, 72:157-161.
14. Nolan J.P. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010, 52:1829-1835.
15. Thaker P.H., Sood A.K. Neuroendocrine influences on cancer biology. Semin Cancer Biol 2008, 18:164-170.
16. Liao X., Che X., Zhao W., Zhang D., Bi T., Wang G. The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappaB signaling. Oncol Rep 2010, 24:1669-1676.
17. Al-Wadei H.A., Al-Wadei M.H., Schuller H.M. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009, 20:477-482.
18. Dietrich P., Moleda L., Kees F., et al. Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: impact of exogenous neuropeptide Y. J Hepatol 2013, 58:254-261.
19. Kassahun W.T., Guenl B., Ungemach F.R., Jonas S., Abraham G. Expression and functional coupling of liver β2-adrenoceptors in the human hepatocellular carcinoma. Pharmacology 2012, 89:313-320.
20. Szabo G., Lippai D. Molecular hepatic carcinogenesis: impact of inflammation. Dig Dis 2012, 30:243-248.
21. Coulouarn C., Corlu A., Glaise D., Guenon I., Thorgeirsson S.S., Clement B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012, 72:2533-2542.
22. Nishikawa T., Nakajima T., Katagishi T., et al. Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int 2009, 29:846-856.
23. Dapito D.H., Mencin A., Gwak G.Y., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
24. Reiberger T., Ferlitsch A., Payer B.A., et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013, 58:911-921.
25. Freestone P.P., Williams P.H., Haigh R.D., Maggs A.F., Neal C.P., Lyte M. Growth stimulation of intestinal commensal Escherichia coli by catecholamines: a possible contributory factor in trauma-induced sepsis. Shock 2002, 18:465-470.
26. Green B.T., Lyte M., Chen C., et al. Adrenergic modulation of Escherichia coli O157:H7 adherence to the colonic mucosa. Am J Physiol Gastrointest Liver Physiol 2004, 287:G1238-G1246.
27. Sperandio V., Torres A.G., Jarvis B., Nataro J.P., Kaper J.B. Bacteria-host communication: the language of hormones. Proc Natl Acad Sci 2003, 100:8951-8956.
28. Worlicek M., Knebel K., Linde H.J., et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut 2010, 59:1127-1134.
29. Sanders V.M., Straub R.H. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun 2002, 16:290-332.
30. Shilov Y., Orlova E. Adrenergic regulation of phagocytic activity of peripheral blood neutrophils, monocytes, and eosinophils in stressed rats. Bull Exp Biol Med 2000, 129:477-479.
31. Zapater P., Gomez-Hurtado I., Peiro G., et al. Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. PLoS One 2012, 7:e43371.
32. Ajakaiye M.A., Jacob A., Wu R., et al. Upregulation of Kupffer cell alpha2A-adrenoceptors and downregulation of MKP-1 mediate hepatic injury in chronic alcohol exposure. Biochem Biophys Res Commun 2011, 409:406-411.
33. Izeboud C.A., Hoebe K.H.N., Grootendorst A.F., et al. Endotoxin-induced liver damage in rats is minimized by β2-adrenoceptor stimulation. Inflamm Res 2004, 53:93-99.
34. Sancho-Bru P., Bataller R., Colmenero J., et al. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2006, 291:G877-G884.
35. Tighe D., Moss R., Bennett D. Porcine hepatic response to sepsis and its amplification by an adrenergic receptor alpha1 agonist and a beta2 antagonist. Clin Sci 1998, 95:467-478.
36. Hamdy N., El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012, 261:292-299.
37. Yu L.X., Yan H.X., Liu Q., et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010, 52:1322-1333.
38. Yoshida, S, Kornek, M, Ikenaga, N, et al. Sub-lethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology (2013). http://dx.doi.org/10.1002/hep.26526. [Epub ahead of print].
39. Zhang H.L., Yu L.X., Yang W., et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 2012, 57:803-812.
40. Lamy S., Lachambre M.P., Lord-Dufour S., Beliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010, 53:200-208.
41. Hernandez-Gea V., Aracil C., Colomo A., et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol 2012, 107:418-427.
42. Serste T., Melot C., Francoz C., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010, 52:1017-1022.
43. Krag A., Bendtsen F., Moller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites?. Hepatology 2011, 53:370-371.
44. Kim T.W., Kim H.J., Chon C.U., et al. Is there any vindication for low dose nonselective beta-blocker medication in patients with liver cirrhosis?. Clin Mol Hepatol 2012, 18:203-212.
45. Nkontchou G., Aout M., Mahmoudi A., et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res 2012, 5:1007-1014.
46. Thiele, M, Gluud, LL, Dahl, E, Krag, A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3(8): http://dx.doi.org/10.1136.
47. Thiele M., Gluud L.L., Kimer N., Dahl E., Krag A. Incidence of hepatocellular carcinoma in precirrhotic and cirrhotic chronic B and C hepatitis: systematic review with data from 39 trials and 10.231 patients. Hepatology 2012, 56:447. abstract 524.
48. Jepsen P., Ott P., Andersen P.K., Sorensen H.T., Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012, 156:841-847. W295.
49. Mancebo A., González-Diéguez M.L., Cadahía V., et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol 2013, 11:95-101.
50. Augustin S., González A., Badia L., et al. Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology 2012, 56:706-714.
51. Ripoll C., Groszmann R.J., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009, 50:923-928.
52. Bañares R., Núñez O., Escudero M., et al. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 2005, 41:566-571.
53. Abraldes J.G., Albillos A., Bañares R., et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651-1658.
54. Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144:323-332.
55. Trebicka J., Hennenberg M., Odenthal M., et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010, 53:702-712.
56. Lok A.S. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?. J Gastroenterol Hepatol 2011, 26:221-227.
57. Strack I., Schulte S., Varnholt H., et al. Beta-adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest 2011, 91:252-261.
58. Turnes J., Hernández-Guerra M., Abraldes J.G., et al. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology 2006, 43:34-41.